<DOC>
	<DOCNO>NCT01357642</DOCNO>
	<brief_summary>This clinical study evaluate 12-week efficacy safety Epinephrine HFA Inhalation Aerosol HFA propose HFA formulation meter dose inhaler ( MDI ) Epinephrine , comparison Placebo-HFA control MDI currently market PrimateneÂ® Mist ( epinephrine CFC inhaler ) , adolescent adult subject asthma .</brief_summary>
	<brief_title>Epinephrine Inhalation Aerosol USP : For Evaluation Of Efficacy And Safety In Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>Patients document asthma , require inhale epinephrine beta 2agonist treatment . No significant change asthma therapy asthmarelated hospitalization emergency visit , within 4 week prior Screening Can tolerate withholding treatment inhale bronchodilator allow medication minimum washout period . Demonstrating Screening Baseline FEV1 50 90 % predict normal value . Demonstrating least 12 % Airway Reversibility . Demonstrating satisfactory technique use metereddose inhaler hand hold peak expiratory flow meter . Female patient childbearing potential must nonpregnant nonlactating Screening throughout study , must use acceptable method contraception study . A smoking history 10pack year , smoke within 12 month screen . Any current past medical condition , per investigator discretion , might significantly affect response study drug , asthma . Concurrent clinically significant disease . Known intolerance hypersensitivity component study drug . Recent infection respiratory tract , screen . Use prohibit medication . Having investigational drug/device study last 30 day prior screen . Known highly suspected substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>bronchial asthma</keyword>
	<keyword>shortness breath</keyword>
</DOC>